Know Labs, Inc. (NYSE American: KNW) is a life sciences company focused on the development and commercialization of noninvasive sensing technologies for health monitoring. At the heart of its technology portfolio is Bio-RFID, a proprietary spectroscopy platform designed to detect and quantify biomarkers in bodily fluids without the need for needles or consumable test strips. By measuring the unique radio frequency signatures of molecules, Know Labs aims to enable real-time, painless monitoring of blood glucose, hydration levels, alcohol content and other key health indicators.
The company’s flagship product, called the SCOUT® device, is engineered to deliver immediate, continuous readings by simply placing a portion of the body near the scanner. With its small form factor and rapid measurement capability, SCOUT is intended for use across home, clinical and point-of-care settings. Know Labs is also exploring applications of its Bio-RFID platform in veterinary diagnostics and environmental testing, positioning the technology for broad, cross-industry deployment.
Founded under the name Visualant in the late 1990s, the firm initially focused on optical metrology and anti-counterfeiting solutions. Around 2017, management pivoted toward biomedical sensing, leveraging decades of research into RF spectroscopy. Since that strategic shift, Know Labs has secured multiple patents covering its sensor architecture and signal-processing algorithms. The company has engaged in pilot studies with academic institutions and healthcare partners to validate performance and is advancing regulatory clearances, including 510(k) submissions with the U.S. Food and Drug Administration.
Headquartered in Seattle, Washington, Know Labs maintains a small executive team with deep backgrounds in medical devices, spectroscopy and regulatory affairs. Its leadership includes experts who have previously guided successful product launches in biosensing and diagnostics. With a growing research and development operation in North America, the company is positioning its Bio-RFID platform for global commercialization as it moves toward scaled manufacturing and broader market entry.
AI Generated. May Contain Errors.
